Integrating UGT1A1 testing within the broader framework of precision oncology represents a significant advance in personalized cancer treatment; as pharmacogenomic testing becomes more widely available, an increasing number of patients will benefit from individualized irinotecan dosing, leading to improved outcomes and reduced risks of severe toxicities. The gene discussed is UGT1A1; the disease is cancer.